Kanabo Group’s CBD-based formula nears international patent approval
(KNB ) said its CBD and nicotine formula is near to becoming an approved patent in the US, UK, and the EU as it has progressed into its next phase of development.
Before today, the Israeli-based medicinal cannabis firm’s CBD-based ‘smoking cessation’ formula was in the Patent Cooperation Treaty (PCT) phase, a process which assists in seeking patent protection internationally for their inventions (in this case, Kanabo’s formula).
Today, Kanabo said its formula has now moved into the National Phase in the US, UK, and EU countries, the final phase before the asset can become an internationally approved patent.
The Company explained to its shareholders that its CBD-based formula can be used to treat nicotine and tobacco addiction, and that evidence suggests that the programme significantly reduces physical and psychological nicotine withdrawal effects by an average of 70%.
Specifically, Kanabo’s formula is targeted at both the traditional smoking and e-cigarettes markets which together are expected to reach £50m over the coming years, the Group noted.
Earlier this year, Kanabo told investors that it had developed and launched the first medical cannabis vape formula in the United Kingdom aimed at initially targeting pain management.
Its VapePod product, which is based on a formula developed and tested in Israel, has been produced in a certified GMP medical facility in full compliance with ISO13485, a standard that is often seen as the first step in achieving compliance with European regulatory requirements.
Avihu Tamir, CEO Kanabo, said, "Our unique patent pending CBD formulations and controlled and consistent delivery device, the VapePod, represents an excellent opportunity for governments to quickly end the reliance on tobacco for millions of citizens worldwide.
He added that, “Our tests show a dramatic reduction in nicotine consumption, whether in cigarettes or e-cigarettes, which can only be good news for health services around the world."
The Company’s application covers ‘a unique new formula of specific naturally derived terpenes to allow the application of a very consistent and reproducible, high concentration of CBD throughout the life of the Kanabo cartridge.’ Initially, CBD is combined with Nicotine, which is then reduced over several weeks until there is zero Nicotine presence, it explained.
Kanabo Group said its new IP offers ‘a novel and effective way; to reduce smoking and potentially complete withdrawal from Nicotine and e-cigarette addiction’ at a time when countries worldwide are continuing to seek measures to reduce tobacco smoking.
Last week, Kanabo said it had applied to undertake a bioavailability and efficacy trial of its proprietary Cannabis inhalation formulas used in conjunction with its VapePod device.
The Company explained that one of the outcomes of this three month trial would be an approval that would enable it to sell its VapePod device and formulas in the Israeli market. If approved, this would be the first cannabis vape cartridges in the Israeli market, it explained.
Kanabo said the three month trial would also support sales in both the UK and Germany by providing physicians and the medical establishments with evidence-based medicine.
The Company also noted that the trial is expected to be the first clinical trial for a cannabis vape pen in the world and that it would therefore provide bioavailability and efficacy data.
The Company believes that by providing high bioavailability and exhibiting rapid onset, its VapePod can deliver cannabis-based treatments “more safely and simply than ever before.”
At 70% THC, the purity of the end product makes it amenable to use in the handheld device, which also allows doctors to administer the medication via precision micro-dose, it outlines.
In doing so, the company said VapePod can provide a more effective method of delivery than compared with smoked cannabis, ‘without the health implications, and allows accurate data to be collected by researchers developing effective treatment regimens at the same time.’
Kanabo, in partnership with Seach Medical Group, has submitted a clinical trial protocol for approval at the Hadassah Medical Centre and subsequent review by the Helsinki Committee.
The trial will test the impact from the inhalation of various Cannabis formulas via its the VapePod, which dispenses standardised and metered inhalations, on healthy volunteers.
As part of the three month trial, participants will undertake a pharmacokinetic (“PK”) analysis to define THC and CBD Absorption, Distribution, Metabolism and Excretion (“ADME”) following the administration of the Company’s proprietary VapePod Formulas, it outlined.
Kanabo said the trial will target the growing segments of the medicinal cannabis market for patients who want to manage their pain using ‘a clean and measurable method of treatment.’
Follow News & Updates from here:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.